Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.30 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25322907 | 0.91 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBHTT | |
| SCHEMBL25320978 | 0.85 | PI4KA (0.49) | PI4KAPI4K2BPI4K2API4KBHTT | |
| SCHEMBL25899012 | 0.79 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBHTT | |
| SCHEMBL25320029 | 0.78 | PDE2A (0.33) | PI4KAPI4K2BPI4K2API4KBKMT2A | |
| SCHEMBL30886293 | 0.77 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBHTT | |
| SCHEMBL25324020 | 0.76 | PDE2A (0.33) | PI4KAPI4K2BPI4K2API4KBKMT2A | |
| SCHEMBL25899217 | 0.76 | PI4KA (0.43) | PI4KAPI4K2BPI4K2API4KBKMT2A | |
| SCHEMBL31178973 | 0.76 | AXL (0.43) | PI4KAPI4K2BPI4K2API4KBHTT | |
| SCHEMBL15081232 | 0.75 | ALDH1A1 (0.35) | PI4KAPI4K2BPI4K2API4KBHTT | |
| SCHEMBL25324023 | 0.75 | PDE2A (0.32) | PI4KAPI4K2BPI4K2API4KBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376484-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-11 | — | — | US | disclosed |
| WO-2025245003-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4469445-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | PI4KA 4827/4885PI4K2B 4833/4885PI4K2A 4785/4885 |
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | PI4KA 4818/4885PI4K2B 4506/4885PI4K2A 4714/4885 |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | PI4KA 4819/4885PI4K2B 4667/4885PI4K2A 4765/4885 |
| US-20250376484-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | PI4KA 2234/4885PI4K2B 2147/4885PI4K2A 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.